Blémarine is a remedy for the treatment of kidney disease (nephrolithiasis). The drug promotes alkalization of urine and has a nephrolitic effect.
Release form and composition
Available medication in the form of effervescent tablets and granules, from which they prepare a solution for oral administration.
The composition of tablets Blémaren includes:
- 1.197 g of citric acid;
- 967.5 mg of potassium bicarbonate;
- 835.5 mg of sodium citrate;
- Excipients: mannitol, macrogol 6000, lactose monohydrate, adipic acid, sodium saccharinate, lemon flavoring.
Tablets are sold in 20 pcs. in plastic tubes complete with indicator paper and a control calendar.
100 grams of granules Blamaren contains:
- 39.9 g of citric acid;
- 32.25 g of potassium bicarbonate;
- 27.85 g of sodium citrate.
200 g granules are sold in plastic bags complete with measuring spoon, indicator paper, bag clip and a control calendar.
Indications for use
According to the instructions to Blamaren, the drug is intended:
- For the treatment and prevention of urolithiasis (the drug prevents the formation and promotes the dissolution of uric acid calculi; calculi containing oxalates and calcium carbonate; as well as mixed calculi consisting of at least 25% oxalate and uric acid salts);
- To increase the urine pH to indicators of 6.2-6.8 (urine alkalization) in patients undergoing treatment with cytotoxic drugs or drugs, the action of which is aimed at removing uric acid from the body.
As a prophylactic agent, the use of Blémaren is indicated for skin porphyria (porphyrin disease), characterized by impaired pigment metabolism, increased porphyrins in the blood and tissues and their enhanced excretion in feces and urine.
According to the instructions to Blamaren, the use of this drug is contraindicated:
- In acute or chronic renal failure;
- Patients with metabolic disorders, in which the bases in the body accumulate, and acids are removed in an excess amount (including metabolic alkalosis);
- In infectious diseases of the urinary tract, caused by the activity of pathogenic microorganisms that can break down urea;
- People who have a pH (urine pH) above 7.0;
- Patients who are shown to adhere to a strict salt-free diet (for example, in severe hypertension);
- When hypersensitivity to the drug.
Dosing and Administration
Before taking the effervescent tablets and granulated powder is dissolved in 200 ml of fruit juice, alkaline mineral water or tea.
The daily dose of Blémaren is determined by the doctor taking into account the severity and characteristics of the course of the disease. As a rule, it makes 2-6 tablets or 6-18 grams of granules (2-6 measured spoons, in 1 spoon - 3 g). Take the drug after a meal, evenly distributing the dose throughout the day (3-4 doses).
In the case of the correct selection of the dosage, the urine pH value should be within the limits of the indices:
- From 6.2 to 7.0 - if it is necessary to dissolve the calculi formed by the urate salts;
- From 7.5 to 8.5 - if it is necessary to dissolve cystine stones;
- From 7.2 to 7.5 - if the patient is diagnosed with porphyria.
In people undergoing treatment with cytotoxic drugs, the pH during the day should not be less than 7.
When the pH drops below the specified values, it is recommended to revise the dose of Blamaren in the direction of its increase. If the pH is above the specified values, the dosage, respectively, is reduced.
To achieve a pronounced clinical effect, drug treatment is continued for 4-6 months.
Monitoring the effectiveness of therapy (that is, determining the level of urine pH) is carried out using indicator paper three times a day before taking another dose of Blemarin.
The resulting color is compared within 2 minutes with the attached scale, after which the results are recorded in the control calendar.
Patients who have cystine calculi, as well as patients with porphyrin disease, should use a special indicator paper with a pH value from 7.2 to 9.7.
In some cases, the use of Blamaren may be accompanied by heartburn, belching, pain in the epigastric region, diarrhea, flatulence, nausea and vomiting, metabolic alkalosis and edema (due to a delayed sodium in the body).
In the presence of individual intolerance to one or another component of the drug, allergic reactions may develop.
During the period of treatment with Blaemarin, patients should reduce the amount of protein foods consumed and products that contain purine bases. It is also necessary to observe the drinking regimen, which involves the use of at least 1.5-2 liters of fluid during the day.
The average daily dose of the drug is 4 tablets. They contain 1.5 mg of potassium and 0.9 mg of sodium. This should be taken into account by people who follow a diet that limits salt intake.
There is no reliable data on the safety of use of Blemarin during pregnancy and lactation. For this reason, pregnant women are prescribed the drug only in cases of extreme necessity, and during lactation they decide to stop breastfeeding.
Analogues of Blémaren are the following drugs:
- According to the composition of active substances - Soluran;
- According to the mechanism of action - Ginjaleling, Madder dyeing extract, Traceptin, Uralit-U, Urolesan, Uroholesan.
Terms and conditions of storage
From pharmacies Blemaren is released in non-prescription mode. According to the manufacturer’s recommendations, it should be stored in its original packaging at a temperature not exceeding 30 ºС. After opening, protect from moisture! Shelf life of tablets - 2 years, granules - 3 years.